Business
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the &#...
About this update from Xortx Therapeutics, Inc.
[{"type":"text","content":"XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders\nCALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, 2026 (the “Meeting”), three new director nominees will be proposed for election in the place of three of the current nominees. At the Meeting, Messrs. George Scorsis, Richard Grieve and Mika Grasso (collectively, the “New Nominees”) will be nominated for election to the Company’s board of directors (the “Board”) instead of Ms. Krysta Davies Foss and Messrs. Raymond Pratt and Paul Van Damme. The Company is currently in negotiations with respect to a significant financing initiative. It is a condition of that financing that the New Nominees be added to the Board in place of the three existing nominees referenced above. In the event that the financing is not completed, the New Nominees will resign from the Board with those vacancies being filled in due course by the Company. The financing is subject to the approval of the TSXV Venture Exchange. Below are biographies for the New Nominees: George Scorsis (Toronto, Canada) - George Scorsis is a results-focused executive with over 20 years of leadership experience in highly regulated sectors such as pharmaceuticals, and consumer-packaged goods. Exceptional at scaling businesses, optimizing operations, and managing complex environments, he has led multi-million dollar businesses through transformative growth. George was the President of Red Bull Canada and was instrumental in establishing the company in the country, driving the brand to 44% market share with market-leading status. His experience in brand strategy and regulatory compliance positioned him to work with Health Canada to develop industry-wide frameworks for the energy drink industry. George moved into the cannabis sector as President of Mettrum Health Corp., where he helped the company become one of Canada’s premier licensed...